Mantle Cell Lymphoma News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

FDA approves new treatment for adults with mantle cell lymphoma - FDA.gov



Medscape
 
FDA approves new treatment for adults with mantle cell lymphoma 
FDA.gov
The U.S. Food and Drug Administration today granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy. ?Mantle cell lymphoma is a particularly aggressive ...
FDA Approves Acalabrutinib (Calquence) for Mantle Cell Lymphoma Medscape
FDA Approves Calquence for Mantle Cell Lymphoma Curetoday.com
Calquence Approved for Mantle Cell Lymphoma U.S. News & World Report
OncLive  -Pharmacy Times  -ClinicalTrials.gov  -MPR 
all 85 news articles » 


FDA approves AstraZeneca's Calquence for mantle cell lymphoma - The Cancer Letter Publications



FDA approves AstraZeneca's Calquence for mantle cell lymphoma 
The Cancer Letter Publications
AstraZeneca and its hematology research and development center of excellence, Acerta Pharma, said the FDA has granted accelerated approval to Calquence (acalabrutinib, previously known as ACP-196), a kinase inhibitor, for the treatment of adult ...

 


Survival Prolonged in MCL With Maintenance Rituximab Following ASCT - Targeted Oncology



Targeted Oncology
 
Survival Prolonged in MCL With Maintenance Rituximab Following ASCT 
Targeted Oncology
According to results from the phase III phase III LyMa trial published in the New England Journal of Medicine, survival was improved for patients with mantle cell lymphoma with maintenance rituximab (Rituxan) following autologous stem-cell ...

 


Acalabrutinib MCL Approval Raises Sequencing Questions - OncLive



OncLive
 
Acalabrutinib MCL Approval Raises Sequencing Questions 
OncLive
The October 2017 FDA approval of acalabrutinib (Calquence) for patients with mantle cell lymphoma (MCL) added another BTK inhibitor to the armamentarium while contributing to the growing discussion of sequencing with other available agents, explained ...

 


Dr. Epperla on Treatment Following Ibrutinib in MCL - OncLive - OncLive



OncLive
 
Dr. Epperla on Treatment Following Ibrutinib in MCL - OncLive 
OncLive
Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University (OSU) Comprehensive Cancer Center, assistant professor in internal medicine, OSU ...

and more » 


Goy Shares Insight on Novel Therapies in MCL - OncLive



OncLive
 
Goy Shares Insight on Novel Therapies in MCL 
OncLive
In an interview with OncLive, Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, Hackensack Medical Center, discussed the excitement surrounding novel ...

 


Comprehensive Analysis of the Growth Factor Histone Deacetylase 8 with Pipeline Assessment in H2 2017 - Digital Journal



Comprehensive Analysis of the Growth Factor Histone Deacetylase 8 with Pipeline Assessment in H2 2017 
Digital Journal
... Cell Carcinoma and T-Cell Leukemia, Central Nervous System, Peripheral T-Cell Lymphomas (PTCL), Gastrointestinal, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Infectious Disease and Musculoskeletal Disorders, Mantle Cell Lymphoma, ...

 


MCL Research Must Refocus on Sequencing, Goy Says - Targeted Oncology



Targeted Oncology
 
MCL Research Must Refocus on Sequencing, Goy Says 
Targeted Oncology
Goy: ZUMA-2 uses CD19-targeted CAR T cells dedicated for MCL in patients who have failed prior therapy, including ibrutinib. We know that patients who have failed ibrutinib typically have very poor outcomes, and those patients have seen multiple therapies.

 


Mantle Cell Lymphoma Market Assessment by Products, Drug ... - MilTech



Mantle Cell Lymphoma Market Assessment by Products, Drug ... 
MilTech
Mantle Cell Lymphoma ? Pipeline Review, H2 provides an overview of the Mantle Cell Lymphoma pipeline landscape. Mantle Cell Lymphoma Market report ...

and more » 


Acalabrutinib receives FDA go-ahead for mantle cell lymphoma - medwireNews



Acalabrutinib receives FDA go-ahead for mantle cell lymphoma 
medwireNews
medwireNews: The kinase inhibitor acalabrutinib has been approved by the US Food and Drug Administration for the treatment of adults with mantle cell lymphoma who have received at least prior treatment. The oral agent, which is targeted for patients ...